Extensive Data Reach STATinMED offers comprehensive real-world data covering over 80% of the US healthcare system, including pharmacy and medical claims across all payer types and geographic regions. This vast coverage enables health solutions companies to access detailed patient-level insights, making it a valuable partner for organizations seeking wide-reaching epidemiological and outcomes data to support product development and market access strategies.

Rapid Customization With the recent launch of their RWD Custom Registry and rapid project kick-off within one week, STATinMED demonstrates a strong capacity to deliver tailored data solutions quickly. This agility offers opportunities to develop customized studies or real-world evidence reports for clients looking to accelerate drug development timelines or meet specific post-market surveillance needs.

Advanced Patient Tracking STATinMED's ability to longitudinally track approximately 300 million de-identified patients across multiple care settings and geographic regions provides detailed patient journey insights. This capability is ideal for organizations interested in health outcome research, patient segmentation, or evaluating real-world treatment patterns and adherence, enhancing competitive positioning in evidence generation.

Engaged Healthcare Network By capturing data from a wide array of healthcare providers, including 97% of healthcare professional specialties, and covering entire pharmacy and prescription cycles, STATinMED can facilitate collaborations with both provider networks and payers. This offers opportunities to develop value-based programs, payer-provider insights, or targeted interventions based on real-world treatment and economic data.

Strong Industry Presence Having been acquired by Ancor Capital and led by experienced professionals like Vice President of HEOR Ami Claxton, STATinMED is positioned for growth within the health economics and outcomes research space. Its established reputation combined with a sizable revenue base signals stability and potential for future collaborations, especially with large biopharma firms seeking advanced real-world evidence capabilities.